The FDA has accepted Belite Bio’s application for tinlarebant and [...]

ATSN-401, Atsena Therapeutics’ investigational gene therapy for Stargardt disease, has [...]

AAVantgarde Bio has received two regulatory milestones for its investigational [...]

AAVantgarde’s AAVB-039 gene therapy, targeting the root cause of Stargardt [...]

Ascidian Therapeutics has appointed Murray Abramson as chief development officer. [...]

Funding will support clinical development of SB-007 and expand pipeline [...]